60 Degrees Pharmaceuticals Announces FDA Orphan Drug Designation For Tafenoquine To Treat Acute Babesiosis
Portfolio Pulse from Benzinga Newsdesk
60 Degrees Pharmaceuticals has received FDA Orphan Drug Designation for tafenoquine to treat acute babesiosis. This designation provides incentives like market exclusivity, tax credits, and fee exemptions. The company has also partnered with Tufts Medical Center to conduct a clinical trial for tafenoquine's efficacy and safety in treating human babesiosis.
June 11, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
60 Degrees Pharmaceuticals (SXTP) has received FDA Orphan Drug Designation for tafenoquine to treat acute babesiosis, which provides market exclusivity, tax credits, and fee exemptions. The company is also partnering with Tufts Medical Center for clinical trials.
The FDA Orphan Drug Designation is a significant milestone for SXTP, providing financial incentives and market exclusivity, which are likely to positively impact the stock price. The partnership with Tufts Medical Center for clinical trials further strengthens the company's position.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100